Sisram Medical Ltd Schedules Board Meeting to Approve 2025 Annual Results and Consider Final Dividend

Date: 6 March 2026
Company: Sisram Medical Ltd (Stock Code: 1696)
Location: Hong Kong

Key Highlights

• Upcoming Board Meeting: Sisram Medical Ltd, a company incorporated in Israel and listed on the Hong Kong Stock Exchange, has announced that its board of directors will convene a meeting on Monday, 23 March 2026.
• Purpose of the Meeting: The primary agenda of this meeting is to consider and approve the annual results of the Group for the year ended 31 December 2025.
• Dividend Recommendation: The board will also discuss and potentially recommend a final dividend for shareholders, if any, for the 2025 financial year.
• Other Business: The board may transact any other business matters during this meeting.

Details for Shareholders

• Price-Sensitive Information: The approval of annual results and the potential recommendation of a final dividend are both events that are highly relevant to shareholders and could impact the company’s share price. Investors should pay close attention to the outcomes of this board meeting.
• Dividend Decision: The declaration of a final dividend, if approved, would provide direct returns to shareholders and may signal the company’s confidence in its financial health and future prospects.
• Board Composition: As of the date of this announcement, the board consists of a mix of executive, non-executive, and independent non-executive directors, led by Chairman Lior Moshe Dayan. The diversity of the board may influence the company’s strategic direction and governance.
• Annual Results Disclosure: The forthcoming annual results will provide investors with detailed insights into the company’s performance over the past year, including revenue, profit margins, and other key financial metrics, which are critical for investment decisions.

What Investors Should Watch

• The announcement of the board meeting date signals that financial results and any dividend decisions are imminent.
• Investors should monitor the company’s disclosures closely on or after 23 March 2026 for updates on the board’s decisions.
• Any positive surprises in the annual results or the declaration of a dividend could act as catalysts for a potential share price movement.
• Conversely, any disappointment in financial performance or the absence of a dividend could negatively affect investor sentiment.

Board Members

The current board is composed of:

• Executive Directors: Mr. Lior Moshe Dayan (Chairman), Mr. Jiahong Li
• Non-Executive Directors: Mr. Yi Liu, Ms. Rongli Feng, Ms. Caroline Xiaokui Jin
• Independent Non-Executive Directors: Mr. Heung Sang Addy Fong, Mr. Chi Fung Leo Chan, Ms. Jenny Chen, Mr. Kai Yu Kenneth Liu

Conclusion

The upcoming board meeting of Sisram Medical Ltd is a key event for shareholders and investors. The consideration of annual results and a potential dividend recommendation for the financial year 2025 are both significant developments that could influence the company’s stock price. Investors are advised to stay informed and review the company’s official disclosures following the board meeting.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a professional financial adviser before making investment decisions. The company’s actual performance and subsequent announcements may differ from the expectations expressed herein.

View SISRAM MED Historical chart here